Marjorie Robert-Guroff, Bijan Safai, Edward P. Gelmann, Peter W.A. Mansell, Jerome E. Groopman, Gurdip S. Sidhu, Alvin E. Friedman-Kien, Anne C. Bayley, Douglas W. Blayney, Michael Lange, Jordan W. Gutterman, James L. Goedert, Neal H. Steigbigel, Joyce M. Johnson, Robert Downing, Robert C. Gallo

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Serum samples from 440 acquired immunodeficiency syndrome (AIDS) patients or individuals at risk for AIDS were examined by the enzyme-linked immunosorbent assay technique for antibodies to HTLV-I core proteins. Specific antibodies were detected in 7% of AIDS patients, 7% of patients with lymphadenopathy, 0% of healthy homosexual men, and 12% of healthy Haitians. When findings in homosexual men were analysed separately, the prevalence for homosexual men with lymphadenopathy was 7% and for homosexuals with AIDS, 6%. Antibody titres ranged from 77 to 74 000. The antibodypositive cases included intravenous drug users, a Haitian AIDS patient, a recipient of multiple blood transfusions, and homosexual men. Haemophiliacs were not examined. Although HTLV-I-specific antibodies are more prevalent in AIDS patients than in healthy US donors, the difference is not sufficient to suggest an association of HTLV-I with the disease. The low rate may indicate an opportunisitic infection of AIDS patients by HTLV-I, or a crossreaction with the recently described HTLV variant, HTLV-III, believed to be the aetiological agent of AIDS. Whether HTLV-I normally exerts immune suppressive effects in vivo with biological consequences remains to be determined.

Original languageEnglish (US)
Pages (from-to)128-131
Number of pages4
JournalThe Lancet
Issue number8395
StatePublished - Jul 21 1984
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'HTLV-I-SPECIFIC ANTIBODY IN AIDS PATIENTS AND OTHERS AT RISK'. Together they form a unique fingerprint.

Cite this